Premium
Facility and personnel factors influencing magnesium sulfate use for eclampsia and pre‐eclampsia in 3 Indian hospitals
Author(s) -
Barua Alka,
Mundle Shuchita,
Bracken Hillary,
Easterling Thomas,
Winikoff Beverly
Publication year - 2011
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2011.07.016
Subject(s) - eclampsia , medicine , health facility , health care , medical emergency , nursing , family medicine , environmental health , health services , pregnancy , population , genetics , biology , economic growth , economics
Objective To identify factors at the health facility and health professional levels that might hinder or facilitate the appropriate use of magnesium sulfate for the treatment of pre‐eclampsia and eclampsia. Methods Seven focus group discussions were conducted with a purposively sampled group of obstetricians/gynecologists, medical residents, and nurses at 3 hospitals in Nagpur, India. Data were collected on facility and drug availability, criteria for diagnosis and management of pre‐eclampsia and eclampsia, attitudes about magnesium sulfate use, and perceived barriers to the treatment of pre‐eclampsia and eclampsia. Results Senior gynecologists seemed to encourage the use of magnesium sulfate, especially management prior to transfer to a higher facility. However, clinicians noted a lack of specific institutional guidelines on dose, timing, and indications, particularly in cases in which delivery was not imminent. In all facilities, service providers noted that their clinical care decisions were sometimes influenced by political and social factors, making management of eclampsia and pre‐eclampsia cases difficult. Care was further challenged by limited drug availability, particularly at the tertiary‐care center. Conclusion Limited drug supply and lack of specific institutional guidelines, equipment, and trained staff hinder the translation of evidence‐based policy on magnesium sulfate into practice.